Baricitinib-d5

Baricitinib-d5 is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

Product Specifications

CAS Number

[1564241-79-7]

Product Name Alternative

LY3009104-d5; INCB028050-d5

UNSPSC

12352005

Target

JAK

Type

Isotope-Labeled Compounds

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Inflammation/Immunology

Purity

98.98

Solubility

10 mM in DMSO

Smiles

N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(C([2H])([2H])C([2H])([2H])[2H])=O)C1

Molecular Formula

C16H12D5N7O2S

Molecular Weight

376.45

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184 (9) :5298-307.|[3]Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2 (4) :351-5.|[4]Khan IM, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration resistance. Int J Obes (Lond) . 2015 Nov;39 (11) :1607-18.